These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 15150619

  • 1. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
    Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, Liu HT, Li CC, Chen JS, Wu CY, Cheng AL.
    Br J Cancer; 2004 May 04; 90(9):1715-9. PubMed ID: 15150619
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK.
    Cancer; 2005 Jan 01; 103(1):111-8. PubMed ID: 15558814
    [Abstract] [Full Text] [Related]

  • 3. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
    Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinländer GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W.
    Oncology; 1999 Apr 01; 56(3):177-80. PubMed ID: 10202270
    [Abstract] [Full Text] [Related]

  • 4. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L, Berger AW, Beutel AK, Gallmeier E, Angermeier S, Fischer von Weikersthal L, Goetze TO, Muche R, Seufferlein T, Ettrich TJ.
    BMC Cancer; 2019 Oct 23; 19(1):990. PubMed ID: 31646981
    [Abstract] [Full Text] [Related]

  • 5. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ.
    Cancer; 2001 Sep 15; 92(6):1567-76. PubMed ID: 11745236
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
    Hwang IG, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC.
    Cancer Chemother Pharmacol; 2015 Apr 15; 75(4):757-62. PubMed ID: 25677446
    [Abstract] [Full Text] [Related]

  • 9. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ, Griffith KA, Kim EJ, Ruch JM, McDonnell KJ, Zalupski MM.
    Am J Clin Oncol; 2018 Feb 15; 41(2):128-132. PubMed ID: 26535993
    [Abstract] [Full Text] [Related]

  • 10. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.
    Lancet Gastroenterol Hepatol; 2017 May 15; 2(5):337-346. PubMed ID: 28397697
    [Abstract] [Full Text] [Related]

  • 11. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
    Chen JS, Lin YC, Jan YY, Liau CT.
    Anticancer Drugs; 2001 Apr 15; 12(4):339-43. PubMed ID: 11335790
    [Abstract] [Full Text] [Related]

  • 12. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.
    Am J Clin Oncol; 2009 Aug 15; 32(4):348-52. PubMed ID: 19363436
    [Abstract] [Full Text] [Related]

  • 13. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
    Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, Liau CT.
    Anticancer Drugs; 1998 Jun 15; 9(5):393-7. PubMed ID: 9660535
    [Abstract] [Full Text] [Related]

  • 14. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.
    Anticancer Drugs; 2007 Mar 15; 18(3):263-71. PubMed ID: 17264757
    [Abstract] [Full Text] [Related]

  • 15. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.
    Cancer Invest; 2003 Mar 15; 21(4):489-96. PubMed ID: 14533437
    [Abstract] [Full Text] [Related]

  • 16. Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
    Unal OU, Oztop I, Unek IT, Yilmaz AU.
    Asian Pac J Cancer Prev; 2013 Mar 15; 14(9):5263-7. PubMed ID: 24175811
    [Abstract] [Full Text] [Related]

  • 17. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.
    Invest New Drugs; 2005 Aug 15; 23(4):369-75. PubMed ID: 16012797
    [Abstract] [Full Text] [Related]

  • 18. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX, Van Laethem JL, Michel P, Gay F, Hendlisz A, Forget F, Bleiberg H.
    Eur J Cancer; 2001 Oct 15; 37(15):1828-32. PubMed ID: 11576835
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Oct 15; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.